drugset / Trial / NCT06132126
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
RandomizedSequentialDouble-blindBasic science
Summary
The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.
Timeline
- Start
- 2023-11-17
- Primary completion
- 2024-06-28
- Completion
- 2024-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3938577 | Unknown | — | Subcutaneous |
| Comparator | insulin degludec | Protein / enzyme biologic | — | Subcutaneous |